Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
This PHASE1 trial investigates HIV Infections and is currently completed. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jun 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .